{"article_title": "FDA allows Houston cancer doctor to resume drug trial", "article_keywords": ["fda", "houston", "cancer", "resume", "burzynski", "doctor", "allows", "drug", "trial", "trialphoto", "unlicensed", "stanislaw"], "article_url": "http://www.houstonchronicle.com/business/medical/article/FDA-allows-controversial-cancer-doctor-to-resume-5621132.php", "article_text": "FDA allows Houston cancer doctor to resume drug trial\n\nPhoto: Meenu Bhardwaj, Freelance Dr. Burzynski, photographed in his clinic library, has been a...\n\nFederal regulators have lifted a partial hold on a clinical trial performed by Stanislaw Burzynski, the Houston doctor whose use of an unlicensed cancer drug has made him a hero to some and a charlatan to others.", "article_metadata": {"publisher": "Houston Chronicle", "description": "Federal regulators have lifted a partial hold on a clinical trial performed by Stanislaw Burzynski, the Houston doctor whose use of an unlicensed cancer drug has made him a hero to some and a charlatan to others.  The Burzynski Research Institute Inc. recently announced the U.S. Food and Drug Administration's decision to permit the doctor to continue his research on using antineoplaston injections for some newly diagnosed brain stem cancers.  For more than 35 years, Burzynski has administered his treatment, a synthesized version of human peptides found in blood, drawing desperate patients worldwide to his west Houston clinic despite cries from conventional cancer researchers that Burzynski lacks evidence that the treatment works.  In a written statement, spokeswoman Stephanie Yao said Burzynski provided information her agency sought, including accurate descriptions of common and serious adverse drug reactions and accurate information about tumor shrinkage after antineoplaston treatment.  [...] Jaffe said he and the state medical board continue to discuss its complaint, which the board is amending to include allegations of failing to meet the standard of care and unprofessional conduct in the evaluation and treatment of several patients.  Huntington said Burzynski double-billed her and her insurance company for supplies needed to administer treatments up to about 12 hours a day, which began August 2012 and concluded early in November 2012.  Besides treatment setbacks related to high doses of steroids, Huntington said, an abscess developed around the port implanted in Hall's chest.", "vf": {"section": "business", "unique_id": "premiumchron-article-5621132"}, "author.name": "By Lora Hines", "og": {"site_name": "Houston Chronicle", "description": "Federal regulators have lifted a partial hold on a clinical trial performed by Stanislaw Burzynski, the Houston doctor whose use of an unlicensed cancer drug has made him a hero to some and a charlatan to others.  The Burzynski Research Institute Inc. recently announced the U.S. Food and Drug Administration's decision to permit the doctor to continue his research on using antineoplaston injections for some newly diagnosed brain stem cancers.  For more than 35 years, Burzynski has administered his treatment, a synthesized version of human peptides found in blood, drawing desperate patients worldwide to his west Houston clinic despite cries from conventional cancer researchers that Burzynski lacks evidence that the treatment works.  In a written statement, spokeswoman Stephanie Yao said Burzynski provided information her agency sought, including accurate descriptions of common and serious adverse drug reactions and accurate information about tumor shrinkage after antineoplaston treatment.  [...] Jaffe said he and the state medical board continue to discuss its complaint, which the board is amending to include allegations of failing to meet the standard of care and unprofessional conduct in the evaluation and treatment of several patients.  Huntington said Burzynski double-billed her and her insurance company for supplies needed to administer treatments up to about 12 hours a day, which began August 2012 and concluded early in November 2012.  Besides treatment setbacks related to high doses of steroids, Huntington said, an abscess developed around the port implanted in Hall's chest.", "title": "FDA allows Houston cancer doctor to resume drug trial", "url": "http://www.houstonchronicle.com/business/medical/article/FDA-allows-controversial-cancer-doctor-to-resume-5621132.php", "image": "http://ww4.hdnux.com/photos/25/26/51/5597787/9/rawImage.jpg", "type": "article"}, "twitter": {"site": "@houstonchron", "card": "summary_large_image"}, "date.release": "2014/14/07", "fb": {"app_id": 653292111352579}, "time.release": "19:12", "msvalidate.01": "9451CA04ABC9D1D5C6419C73B4C4F7B7", "news_keywords": "health treatment,medical research,cancer", "sections": "Business,Medical", "viewport": "initial-scale = 1.0, maximum-scale = 1.0, width = device-width", "subject": "health treatment,medical research,cancer"}, "_id": "\"57477af36914bd0286fcc5a7\"", "article_summary": "FDA allows Houston cancer doctor to resume drug trialPhoto: Meenu Bhardwaj, Freelance Dr. Burzynski, photographed in his clinic library, has been a...Federal regulators have lifted a partial hold on a clinical trial performed by Stanislaw Burzynski, the Houston doctor whose use of an unlicensed cancer drug has made him a hero to some and a charlatan to others."}